Tezacaftor
- Generic Name
- Tezacaftor
- Brand Names
- Symdeko, Trikafta (100 Mg / 50 Mg / 75 Mg; 150 Mg)
- Drug Type
- Small Molecule
- Chemical Formula
- C26H27F3N2O6
- CAS Number
- 1152311-62-0
- Unique Ingredient Identifier
- 8RW88Y506K
- Background
Tezacaftor is a drug of the cystic fibrosis transmembrane conductance regulator (CFTR) potentiator class. It was developed by Vertex Pharmaceuticals and FDA approved in combination with ivacaftor to manage cystic fibrosis. This drug was approved by the FDA on February 12, 2018.
...
- Indication
Tezacaftor is combined with ivacaftor in one product for the treatment of cystic fibrosis (CF) in patients aged 12 years or older with two copies of the F508del gene mutation or at least one mutation in the CFTR gene that is responsive to this drug.
...
- Associated Conditions
- Cystic Fibrosis (CF)
- Associated Therapies
- -
Personalized Theratyping Trial
- First Posted Date
- 2018-07-16
- Last Posted Date
- 2023-09-11
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 20
- Registration Number
- NCT03587961
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
A Study to Evaluate Safety and Pharmacokinetics of VX-659 in Healthy Subjects and in Adults With Cystic Fibrosis
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-01-24
- Last Posted Date
- 2017-09-05
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 163
- Registration Number
- NCT03029455
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath